|
Jan 4
|
GSK’s Nucala Gains Approval in China for CRSwNP
|
|
Jan 3
|
GSK's Sinus Disease Drug Secures Approval In China
|
|
Dec 30
|
Can GSK plc (LON:GSK) Maintain Its Strong Returns?
|
|
Oct 11
|
Jim Cramer Says GSK plc (GSK) ‘Goes Higher’
|
|
Oct 10
|
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
|
|
Oct 10
|
Trending tickers: Tata Investment Corporation, Tesla, HSBC, GSK and BMW
|
|
Oct 10
|
FTSE 100 Live 10 October: GSK shares rise on $2.2bn Zantac settlement, property firm gets £1.1bn bid
|
|
Oct 10
|
GSK shares jump after landmark £1.68bn heartburn drug settlement
|
|
Oct 10
|
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
|
|
Oct 10
|
GSK shares jump on $2.2 billion Zantac settlement
|
|
Oct 9
|
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
|
|
Oct 9
|
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
|
|
Oct 9
|
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
|
|
Oct 8
|
US Venture Capital Opens Path to Funding for China Biotech Firms
|
|
Oct 8
|
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
|
|
Oct 8
|
Why Pfizer Will Find It Hard to Appease Its Activist Investor
|
|
Oct 7
|
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
|
|
Oct 7
|
Starboard Value takes $1 billion stake in Pfizer: Reports
|
|
Oct 7
|
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
|
|
Oct 7
|
Millions urged to delete data from mail-order DNA test maker
|